Paper36745446
Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis.
Meier S and 40 others. JAMA Neurol, 2023. Cited by 231 papers, by iCite.
Cite this record
ConductScience Library. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis. Papers, record 36745446. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36745446
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Multiple Sclerosis | Major topic |
| Male | |
| Humans | |
| Female | |
| Adult | |
| Middle Aged | |
| Cohort Studies | |
| Glial Fibrillary Acidic Protein | |
| Intermediate Filaments | |
| Prospective Studies | |
| Disease Progression | |
| Biomarkers | |
| Neurofilament Proteins | |
| Recurrence |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT06871072 | Telerehabilitation for Multiple Sclerosis | Background |
Source ClinicalTrials.gov
Cited by169
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 231 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42975661 | Uncovering disability progression in people with multiple sclerosis: a practical guide. | J Neurol | 2026 | https://conductscience.org/library/papers/42975661 | PubMed |
| 42948123 | A 2-year multimodal prospective cohort study to predict sustained progression independent of relapse activity in multiple sclerosis. | Front Neurol | 2026 | https://conductscience.org/library/papers/42948123 | PubMed |
| 42941936 | Limited Gut Microbiome Differences Between Relapsing-Remitting and Secondary Progressive Multiple Sclerosis: A Shotgun Metagenomic Study. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42941936 | PubMed |
| 42911241 | DELPHI expert consensus-derived factors influencing the early use of monoclonal high-efficacy therapies in treatment-naïve patients with relapsing-remitting multiple sclerosis. | J Neurol | 2026 | https://conductscience.org/library/papers/42911241 | PubMed |
| 42904235 | Beyond biomarker validation: defining when serum neurofilament light chain should influence management in multiple sclerosis. | Front Immunol | 2026 | https://conductscience.org/library/papers/42904235 | PubMed |
| 42897668 | Neural stem cell transplantation in progressive multiple sclerosis: STEMS study long-term outcomes. | Stem Cell Res Ther | 2026 | https://conductscience.org/library/papers/42897668 | PubMed |
| 42879711 | Serum Glial-Related Biomarkers Show Distinct Contributions to Radiologic and Clinical Outcomes in Early Multiple Sclerosis. | Neurol Neuroimmunol Neuroinflamm | 2026 | https://conductscience.org/library/papers/42879711 | PubMed |
| 42819529 | Chimeric antigen receptor T-cell therapy in neuroimmune diseases: mechanistic rationale, clinical experience, and translational challenges. | Front Immunol | 2026 | https://conductscience.org/library/papers/42819529 | PubMed |
| 42814369 | Management of Multiple Sclerosis: Incorporating Recent Advances in Pathophysiology and Diagnosis to Guide Treatment Strategies. | Drugs | 2026 | https://conductscience.org/library/papers/42814369 | PubMed |
| 42809446 | Autologous Hematopoietic Transplantation Reduces Brain Inflammatory and Axoglial Damage Biomarkers in Multiple Sclerosis. | Neurol Neuroimmunol Neuroinflamm | 2026 | https://conductscience.org/library/papers/42809446 | PubMed |
| 42798289 | Serum GFAP and Age Accurately Distinguish AQP4-IgG Positive and Double Seronegative NMOSD From MOGAD After a Recent Attack. | Eur J Neurol | 2026 | https://conductscience.org/library/papers/42798289 | PubMed |
| 42753010 | Impact of age, BMI, and renal function adjustment on interpretation of serum NfL and GFAP in multiple sclerosis progression: a scoping review. | Neurol Sci | 2026 | https://conductscience.org/library/papers/42753010 | PubMed |
| 42751212 | Smoldering neuroinflammation in progressive multiple sclerosis: mechanisms, imaging biomarkers, and therapeutic opportunities. | Front Immunol | 2026 | https://conductscience.org/library/papers/42751212 | PubMed |
| 42728304 | Recognition and management of acute relapse of multiple sclerosis, neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease. | Cell Death Differ | 2026 | https://conductscience.org/library/papers/42728304 | PubMed |
| 42625502 | Interpreting p-tau217 on the ward: frailty and plasma biomarkers in acutely admitted older adults. | Alzheimers Dement | 2026 | https://conductscience.org/library/papers/42625502 | PubMed |
| 42593635 | Genetic Risk in Multiple Sclerosis: Susceptibility, Modifiers and Unresolved Questions. | Neurol Ther | 2026 | https://conductscience.org/library/papers/42593635 | PubMed |
| 42533190 | Comorbidities in multiple sclerosis: acquired hepatocerebral degeneration mimicking disease progression. | Neurol Sci | 2026 | https://conductscience.org/library/papers/42533190 | PubMed |
| 42525242 | Prognostic factors in paediatric-onset multiple sclerosis: a narrative review. | J Neurol | 2026 | https://conductscience.org/library/papers/42525242 | PubMed |
| 42512509 | Beyond Relapses: A Multimodal Biomarker Framework for Progression Independent of Relapse Activity and Smouldering Multiple Sclerosis. | Brain Sci | 2026 | https://conductscience.org/library/papers/42512509 | PubMed |
| 42459947 | Cross-platform comparison of blood glial fibrillary acidic protein quantification in healthy controls and multiple sclerosis. | Mult Scler J Exp Transl Clin | 2026 | https://conductscience.org/library/papers/42459947 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| GFAP | 2670 | PubTator's text mining | https://conductscience.org/library/genes/2670 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36745446
GET https://conductscience.org/api/papers/v1/36745446/authors?page=2